Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Group 1 - Black Diamond Therapeutics, Inc. announced a strategic worldwide licensing agreement for BDTX-4933 with Servier [1] - Following the announcement, the stock initially surged by 65% but later declined to $1.72 [1] Group 2 - The article reflects the author's personal investment position in BDTX, indicating a beneficial long position [2]